FK
Therapeutic Areas
Yuhan Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lecraza (lazertinib) | EGFR T790M+ NSCLC | Approved |
| Lecraza + amivantamab | 1st-line EGFRm NSCLC | Phase 3 |
| YH25448 (lazertinib) | Adjuvant EGFRm NSCLC | Phase 3 |
| JNJ-75276617 (PU-H71) | Acute Leukemia | Phase 1 |
| YH35367 | Gout / Hyperuricemia | Phase 3 |
| YH14618 | Diabetic Retinopathy | Phase 2 |
| YH29528 | Solid Tumors | Phase 1 |
| YH003 | Oncology (with anti-PD-1) | Phase 2 |